All Antibody articles
-
OpinionThe side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance
-
Business
Coronavirus variants stymie success of monoclonal antibodies
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
-
News
UK government faces lawsuit over procurement of Covid immunity test
The health department reportedly knew that the antibody test did not perform as well as claimed when it bought them
-
Business
Regulatory panel unconvinced by Alzheimer’s antibody evidence
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
-
Opinion
Blood offering
Antibodies in various forms could bridge the Covid-19 treatment gap until a vaccine is available
-
Business
Drop in plasma donations hits immunoglobulin supply
Lockdown and social distancing have discouraged donors, and the potential impact of convalescent plasma collection for Covid-19 treatment is unclear
-
Business
What are the risks of fast-tracking a Covid-19 vaccine?
Condensing timelines from years to months inevitably involves compromises
-
Business
Can existing drugs slow Covid-19?
The fastest route to treatments may be to repurpose existing drugs – if they work
-
-
Research
Small molecule finds flu virus’s weak spot
Drug candidate that targets highly conserved region of virus gave mice complete protection from swine flu
-
Research
Forceful treatment stabilises drug antibody linkages
Ultrasonic energy could modify maleimide–thiol connections in cancer treatments in volume
-
News
What is directed evolution and why did it win the chemistry Nobel prize?
If you’ve got questions about yesterday’s chemistry Nobel prize then we’ve got answers
-
News
Vaccines central to efforts to head off latest Ebola outbreak
Ring vaccination strategy could halt disease in its tracks provided health systems can cope
-
Opinion
Rise of the biologics
Antibodies, RNA and gene therapy don’t necessarily compete with small molecule drugs – and they all rely on chemistry
-
Business
Amgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
Business
AstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
Business
Celgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs
-
Business
Seattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
-
Business
Cholesterol drug withdrawn in patent dispute
Ruling that Regeneron’s Praluent antibody infringes Amgen’s Repatha patent could stifle innovation
-
Business
Standard antibody will bolster biopharma
New NIST reference material will help validate and compare analytical techniques
